GC
SNDX icon

Guggenheim Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Guggenheim Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Sell
15,785
-271
-2% -$5.64K ﹤0.01% 1447
2026
Q1 		$375K Buy
16,056
+1,518
+10% +$33K ﹤0.01% 1304
2025
Q4 		$305K Buy
14,538
+2,395
+20% +$41.8K ﹤0.01% 1521
2025
Q3 		$187K Sell
12,143
-605
-5% -$7.92K ﹤0.01% 1525
2025
Q2 		$119K Buy
12,748
+258
+2% +$2.84K ﹤0.01% 1553
2025
Q1 		$153K Buy
12,490
+609
+5% +$8.59K ﹤0.01% 1569
2024
Q4 		$157K Buy
+11,881
New +$203K ﹤0.01% 1623

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Guggenheim Capital's SNDX Position: Q2 2026 in Review

Guggenheim Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 1.7% in Q2 2026, selling an estimated $5.64K and leaving 15,785 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1447.

Guggenheim Capital first reported a position in SNDX in Q4 2024 and has held it in 7 quarters since. The position peaked at $375K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Guggenheim Capital held 15,785 shares of Syndax Pharmaceuticals worth $345K as of Q2 2026.
  • Guggenheim Capital sold 271 Syndax Pharmaceuticals shares in Q2 2026, an estimated $5.64K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1447 holding.
  • Guggenheim Capital first reported a position in Syndax Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Guggenheim Capital's Syndax Pharmaceuticals position peaked at $375K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.